ArticleClinical pharmacology and therapeutics2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 45 citations in OpenAlex.
- Adaptation of the Risk Analysis Index for Frailty Assessment Using Diagnostic Codes.JAMA network open · 2024Article
- Aiding the Adoption of Master Protocols by Optimizing Patient Engagement.Therapeutic innovation & regulatory science · 2023Article
- Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.Diabetes care · 2022Review
- Planning for the Next Pandemic: Ethics and Innovation Today for Improved Clinical Trials Tomorrow.Statistics in biopharmaceutical research · 2022Article
- Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.Human vaccines & immunotherapeutics · 2021Review
- Basket Designs: Statistical Considerations for Oncology Trials.JCO precision oncology · 2019Review
- Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators' perspective.Journal of perinatology : official journal of the California Perinatal Association · 2019Article
- Reporting of master protocols towards a standardized approach: A systematic review.Contemporary clinical trials communications · 2019Article
- Recognizing that Evidence is Made, not Born.Clinical pharmacology and therapeutics · 2019Article
- Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.Clinical pharmacology and therapeutics · 2019Article
- Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.Molecular oncology · 2019Review
- Baseline and extensions approach to information retrieval of complex medical data: Poznan's approach to the bioCADDIE 2016.Database : the journal of biological databases and curation · 2018Article
- Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adaptive, seamless, multisponsor, multitherapy clinical trial designs executed as large scale platforms, could create superior evidence more efficiently than single-sponsor, single-drug trials. These trial PIPELINEs also could diminish barriers to trial participation, increase the representation of real-world populations, and create systematic evidence development for learning throughout a therapeutic life cycle, to continually refine its use. Comparable evidence could arise from multiarm design, shared comparator arms, and standardized endpoints-aiding sponsors in demonstrating the distinct value of their innovative medicines; facilitating providers and patients in selecting the most appropriate treatments; assisting regulators in efficacy and safety determinations; helping payers make coverage and reimbursement decisions; and spurring scientists with translational insights. Reduced trial times and costs could enable more indications, reduced development cycle times, and improved system financial sustainability. Challenges to overcome range from statistical to operational to collaborative governance and data exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.